<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-150570" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Obesity and Type 2 Diabetes</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Yashi</surname>
            <given-names>Kanica</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Daley</surname>
            <given-names>Sharon F.</given-names>
          </name>
          <aff>Cape Cod Hospital, Hyannis, MA</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Kanica Yashi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sharon Daley declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>19</day>
          <month>6</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-150570.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Obesity is a common risk factor for type 2 diabetes. Screening for diabetes is indicated in all patients with obesity. Treating obesity is the cornerstone in the prevention and management of type 2 diabetes. Weight reduction leads to prevention, control, and in some cases, remission of diabetes. This activity reviews the management of patients with obesity and diabetes, including lifestyle interventions, pharmacologic treatment, and metabolic and bariatric surgery.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Determine lifestyle risk factors and plan aggressive modification strategies to initiate treatment.</p></list-item><list-item><p>Select appropriate pharmacologic treatments for patients with coexisting obesity and type 2 diabetes.</p></list-item><list-item><p>Identify the indications for surgical intervention for coexisting obesity and type 2 diabetes.</p></list-item><list-item><p>Collaborate with the interprofessional team to educate, treat, and monitor patients with obesity and type 2 diabetes to improve patient outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=150570&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=150570">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-150570.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Excess body weight and obesity are significant risk factors for type 2 diabetes mellitus (T2DM). Obesity&#x000a0;management in patients with&#x000a0;T2DM should be implemented according to Guidelines from the American Diabetes Association and the American Obesity Association, including lifestyle interventions, pharmacologic treatments, and surgical indications. Leaders at an international consensus conference, the Second Diabetes Surgery Summit (2016), developed&#x000a0;a treatment algorithm for metabolic and bariatric surgery in patients with obesity and diabetes.<xref ref-type="bibr" rid="article-150570.r1">[1]</xref><xref ref-type="bibr" rid="article-150570.r2">[2]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-150570.s3" sec-type="Issues of Concern">
        <title>Issues of Concern</title>
        <p>The lifetime diabetes risk in&#x000a0;men&#x000a0;older than 18 years increases from 7% to 70% when BMI increases from less than 18.5 kg/m to more than&#x000a0;35 kg/m. Similarly, the lifetime diabetes risk in females increases from 12% to 74% with the&#x000a0;same BMI values.<xref ref-type="bibr" rid="article-150570.r3">[3]</xref>&#x000a0;Therefore, screening for diabetes is&#x000a0;indicated in all patients with obesity. Treating obesity is the cornerstone in the prevention and management of T2DM. Weight loss leads to a significant reduction in the incidence of diabetes in at-risk populations. In one study, lifestyle modifications such as modest weight reduction (5-10% of baseline weight) and increased physical activity to at least 150 minutes per week reduced the incidence of diabetes by more than 50%.<xref ref-type="bibr" rid="article-150570.r4">[4]</xref>&#x000a0;</p>
        <p>Similarly, bariatric surgery led to a 5-fold reduction in&#x000a0;T2DM incidence over&#x000a0;7 years.<xref ref-type="bibr" rid="article-150570.r5">[5]</xref>&#x000a0;Weight reduction&#x000a0;is also effective in the treatment of T2DM. Glycemic control improves proportionally with weight loss, sometimes leading to remission.<xref ref-type="bibr" rid="article-150570.r6">[6]</xref>&#x000a0;Treatment&#x000a0;of T2DM&#x000a0;begins with lifestyle management, followed by&#x000a0;pharmacologic treatment and surgical therapy, if indicated.</p>
        <p>The most common metric used to evaluate body weight is body mass index (BMI). BMI&#x000a0;is calculated by dividing the patient's weight by the square of the height (kg/m). BMI&#x000a0;stratifies patients into&#x000a0;the following categories:</p>
        <list list-type="order">
          <list-item>
            <p>Underweight: less than 18.5 kg/m</p>
          </list-item>
          <list-item>
            <p>Healthy&#x000a0;weight: 18.5 to 24.9 kg/m (18.5 to 22.9 kg/m in the Asian population)</p>
          </list-item>
          <list-item>
            <p>Overweight: 25 to 29.9 kg/m (23 to 27.4 kg/m in the Asian population)</p>
          </list-item>
          <list-item>
            <p>Obese, class 1: 30 to 34.9 kg/m (27.5 to 32.4 kg/m in the Asian population)</p>
          </list-item>
          <list-item>
            <p>Obese, class 2: 35 to 39.9 kg/m (32.5 to 37.4 kg/m in the Asian population)</p>
          </list-item>
          <list-item>
            <p>Obese, class 3:&#x000a0;greater than 40 kg/m (greater than 37.5 kg/m in the Asian population)</p>
          </list-item>
        </list>
        <p>The upper&#x000a0;value in each category is&#x000a0;reduced for&#x000a0;individuals of Asian descent&#x000a0;because they tend to have a higher body fat content and increased risk of T2DM at a lower BMI. Many international societies have adopted&#x000a0;these lower ranges to define obesity in individuals of Asian descent.<xref ref-type="bibr" rid="article-150570.r7">[7]</xref>&#x000a0;</p>
        <p>
<bold>Lifestyle Management</bold>
</p>
        <p>Obesity is a chronic medical condition and a known risk factor for the development of T2DM. In patients diagnosed with overweight or obesity and T2DM,&#x000a0;treatment&#x000a0;begins with aggressive modification of lifestyle risk factors.<xref ref-type="bibr" rid="article-150570.r8">[8]</xref>&#x000a0;These modifications include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Self-management education</p>
          </list-item>
          <list-item>
            <p>Nutritional counseling</p>
          </list-item>
          <list-item>
            <p>Increasing physical activity</p>
          </list-item>
          <list-item>
            <p>Psychosocial care, if&#x000a0;indicated</p>
          </list-item>
          <list-item>
            <p>Smoking cessation for smokers</p>
          </list-item>
        </list>
        <p>Patient self-management education promotes a better understanding of coexisting chronic conditions&#x000a0;and improves knowledge about self-testing and compliance with medical therapy. Patient education is first recommended&#x000a0;when T2DM is diagnosed, then annually, and again if complications develop.<xref ref-type="bibr" rid="article-150570.r9">[9]</xref>&#x000a0;Nurses, registered dietitians, primary care providers, and other specialists contribute to patient education. Motivational interviewing, visual aids, handouts, and electronic resources are valuable teaching tools.</p>
        <p>The goal of lifestyle modification is a loss of at least 5% of body weight to achieve beneficial effects.<xref ref-type="bibr" rid="article-150570.r10">[10]</xref>&#x000a0;The Look AHEAD trial provides the most data on the effect of intensive lifestyle intervention (ILI).&#x000a0;This trial&#x000a0;demonstrated sustained weight loss&#x000a0;greater than 5% in at least&#x000a0;half of the participants, and 27% of participants had greater than 10% weight loss at&#x000a0;8 years.<xref ref-type="bibr" rid="article-150570.r11">[11]</xref>&#x000a0;</p>
        <p>Participants assigned to the ILI group required fewer medications for diabetes, hypertension, and lipid management. A calorie deficit of 500&#x000a0;to 750 kcal/day is generally advised to achieve this. Typically, this results in&#x000a0;a calorie goal of 1200&#x000a0;to 1500 kcal/day for women and 1500-1800 kcal/day for men. Meal replacement plans can be&#x000a0;helpful for some individuals in reaching a set calorie deficit, but their use is unlikely to be sustainable over the long term. Other successful dietary interventions include the DASH diet (Dietary Approach to Stop Hypertension) and the Mediterranean diet.<xref ref-type="bibr" rid="article-150570.r12">[12]</xref><xref ref-type="bibr" rid="article-150570.r13">[13]</xref>&#x000a0;</p>
        <p>Modified alternate-day fasting and the 5:2 diet&#x000a0;are the only types of intermittent fasting diets that&#x000a0;have demonstrated a statistically significant weight loss of more than 5%.<xref ref-type="bibr" rid="article-150570.r14">[14]</xref>&#x000a0;</p>
        <p>The diet chosen should be tailored to the patient's cultural and dietary patterns, food availability, and other factors such as hunger and access to healthy foods. Counseling sessions for nutrition, physical activity, and behavioral goals to achieve&#x000a0;weight loss should be available to all patients. More than 16 such sessions in 6 months&#x000a0;are included in standard ILI, and monthly sessions continue for patients who achieve the target weight loss after one year. However, this&#x000a0;degree of intensive intervention may not be readily available or financially feasible in primary care settings.&#x000a0;</p>
        <p>Individuals&#x000a0;with&#x000a0;T2DM and obesity should be encouraged to increase their physical activity gradually. A minimum target of 150 minutes per week of moderate-intensity exercise is recommended. The weekly exercise plan should include aerobic exercise and&#x000a0;two to three&#x000a0;resistance training sessions. Exercising&#x000a0;daily, or at least avoiding more than&#x000a0;2 days between exercise sessions,&#x000a0;promotes decreased insulin resistance.<xref ref-type="bibr" rid="article-150570.r15">[15]</xref></p>
        <p>Screening for mood disorders and other psychosocial factors related to diabetes and&#x000a0;obesity should be done regularly.<xref ref-type="bibr" rid="article-150570.r16">[16]</xref><xref ref-type="bibr" rid="article-150570.r17">[17]</xref>&#x000a0;Treatment of coexisting mental health conditions can improve&#x000a0;compliance and outcomes for patients with obesity and T2DM.</p>
        <p>Teens and adults with obesity and diabetes should be screened for&#x000a0;smoking and other tobacco use, including e-cigarettes. Smoking is associated with increased diabetes risk, possibly by increasing insulin resistance.<xref ref-type="bibr" rid="article-150570.r18">[18]</xref>&#x000a0;Counseling and appropriate pharmacological measures for smoking cessation should be offered to smokers.</p>
        <p>
<bold>Medical Evaluation and Treatment</bold>
</p>
        <p>When lifestyle modifications do not achieve weight loss goals, clinicians should review the patient's medical history for other contributing factors. This includes obesogenic medications such as thiazolidinediones, beta-blockers, sulphonylureas, insulin, risperidone, other antipsychotics, antidepressants, steroids, and gabapentin.&#x000a0;</p>
        <p>Pharmacotherapy is recommended as an adjunct to ILI in patients with a BMI of&#x000a0;greater than&#x000a0;30 kg/m (greater than 25 kg/m in Asians) or greater than 27 kg/m&#x000a0;(greater than 23 kg/m in Asians) with a&#x000a0;weight-related complication&#x000a0;such as hypertension, dyslipidemia, T2DM, or sleep apnea.<xref ref-type="bibr" rid="article-150570.r19">[19]</xref>&#x000a0;</p>
        <p>After initiating therapy, patients should be monitored closely for medication efficacy and&#x000a0;adverse effects. Early responders with a&#x000a0;weight&#x000a0;reduction of at least 5% in the first 12 weeks typically continue&#x000a0;to achieve&#x000a0;sustained and significant weight loss. Most weight loss medications are intended for long-term use. Initially, medical therapy for weight loss was studied only for brief use before the evidence supporting long-term use emerged in the last&#x000a0;2 decades. However, the FDA has approved phentermine only for short-term use of fewer than&#x000a0;12&#x000a0;weeks&#x000a0;due to concerns about possible abuse.&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
        <p>FDA-approved weight loss medications for long-term use are detailed below.</p>
        <p>(1) Phentermine-topiramate, extended-release</p>
        <p>This combination was approved in 2012. The SEQUEL trial investigated this medication and found an average of 10% weight loss compared to less than 2% in the placebo arm.<xref ref-type="bibr" rid="article-150570.r20">[20]</xref>&#x000a0;It is efficacious in patients who are overweight up to class 3 obesity with a BMI of&#x000a0;greater than 45 kg/m. The initial dose is 3.75 mg of phentermine and 23 mg of topiramate ER (3.75/23). This can be titrated up to 15 mg/92 mg in 2-week intervals as tolerated. Common adverse effects include insomnia, increased blood pressure, dry mouth, and paresthesias. It should not be used with a monoamine oxidase inhibitor. Phentermine-topiramate is associated with congenital&#x000a0;malformations such as cleft lip or cleft palate. Pregnancy should be ruled out before prescribing, and contraception&#x000a0;is essential when treating women of childbearing age with this agent.</p>
        <p>(2) Liraglutide, semaglutide, and tirzepatide&#x000a0;</p>
        <p>These medications&#x000a0;are glucagon-like peptide-1 receptor (GLP-1) agonists. They were initially approved for the treatment of T2DM but were found to&#x000a0;be beneficial&#x000a0;for weight loss. Since then, the FDA has approved liraglutide and semaglutide. FDA approval for tirzepatide to treat obesity is expected in 2023.&#x000a0;GLP-1 agonists&#x000a0;promote weight loss by multiple mechanisms, including insulin release stimulation, insulin sensitization, glucagon suppression,&#x000a0;slower gastric emptying, and centrally acting early satiety. These medications&#x000a0;are expensive, and availability can be limited based on insurance coverage.&#x000a0;</p>
        <p>Liraglutide was studied in the SCALE trial and led to about 5%&#x000a0;additional weight loss&#x000a0;compared to the placebo.<xref ref-type="bibr" rid="article-150570.r21">[21]</xref>&#x000a0;Dosing starts at&#x000a0;0.6 mg daily, administered subcutaneously (SC), and titrated at weekly intervals of up to 3 mg daily SC. Gastrointestinal disturbance and nausea are the most common adverse effects.</p>
        <p>Semaglutide was examined in the STEP clinical trial.<xref ref-type="bibr" rid="article-150570.r22">[22]</xref>&#x000a0;Semaglutide administration&#x000a0;led to a 15&#x000a0;to 16% weight loss by week 68. This medication leads to the&#x000a0;most robust weight loss compared to other GLP-1 agonists. The initial dose is 0.25 mg SC weekly and can be increased every&#x000a0;4 weeks to 2.4 mg SC weekly.</p>
        <p>The SURMOUNT-1 trial investigated the use of tirzepatide for weight loss in people with a BMI of more than 30 kg/m or 27 kg/m with diabetes mellitus.<xref ref-type="bibr" rid="article-150570.r23">[23]</xref>&#x000a0;Tirzepatide has a dual mechanism&#x000a0;as a GLP-1 agonist and a glucose-dependent insulinotropic peptide. Approximately 20% weight loss was seen with 15 mg/week SC, the highest dose.</p>
        <p>(3) Naltrexone-bupropion sustained release (SR)</p>
        <p>This combination works by multiple mechanisms to reduce food intake and promote weight loss. Naltrexone is an opiate antagonist, and bupropion is an antidepressant. The medication&#x000a0;must be titrated slowly to avoid intolerance. The starting dose&#x000a0;for naltrexone/bupropion is one 8/90 mg tablet daily.&#x000a0;Then it is&#x000a0;increased to 2 tablets (16mg/180 mg) twice a day if necessary. Use is contraindicated in patients with uncontrolled hypertension, seizure disorder,&#x000a0;or long-term opioid therapy.</p>
        <p>(4) Orlistat</p>
        <p>Orlistat is a pancreatic lipase inhibitor that prevents fat absorption.&#x000a0;Orlistat&#x000a0;is dosed as 60 mg tablets,&#x000a0;3 times&#x000a0;daily with meals. The XENDOS trial showed an approximate 5% weight loss with orlistat.<xref ref-type="bibr" rid="article-150570.r24">[24]</xref>&#x000a0;Adverse events include flatulence, abdominal pain, and fecal urgency, limiting the usefulness of this medication. Orlistat can also lead to a deficiency of fat-soluble vitamins and predispose patients to cholelithiasis and nephrolithiasis.&#x000a0;</p>
        <p>
<bold>Surgical Treatment</bold>
</p>
        <p>Surgical obesity treatment is indicated in patients with suboptimal weight loss or uncontrolled hyperglycemia. Surgery is&#x000a0;recommended for patients with a BMI greater than 40 kg/m or a BMI of 35&#x000a0;to 39.9 kg/m with hyperglycemia, comorbid weight-related conditions, or inability to achieve sustainable weight loss. The&#x000a0;Second&#x000a0;Diabetes Surgery Summit evaluated the&#x000a0;evidence for surgical treatment in patients with a BMI of 30&#x000a0;to 34.9 kg/m.</p>
        <p>Metabolic and bariatric surgery is safe and effective and&#x000a0;should also be considered in diabetic patients with a BMI of 30&#x000a0;to 34.9 kg/m with uncontrolled hyperglycemia despite optimal medical therapy for T2DM. Surgery for obesity includes several options. The most common procedures are Roux-en-Y gastric bypass (RYGB), vertical sleeve gastrectomy (VSG), laparoscopic adjustable gastric banding (LAGB), and biliopancreatic diversion (BPD).<xref ref-type="bibr" rid="article-150570.r2">[2]</xref>&#x000a0;</p>
        <p>RYGB and VSG are the most frequently used techniques as they&#x000a0;have better long-term outcomes and safety data. BPD is very effective but carries a higher risk of complications. LAGB is the safest procedure but carries the highest risk of revision and re-intervention.&#x000a0;</p>
        <p>Surgery achieves results by&#x000a0;altering gastrointestinal (GI) anatomy,&#x000a0;producing early satiety,&#x000a0;decreasing the absorptive surface area, and&#x000a0;modifying hormones responsible for glucose homeostasis.<xref ref-type="bibr" rid="article-150570.r25">[25]</xref>&#x000a0;The&#x000a0;positive effects on intestinal glucose metabolism, changes in pancreatic islet hormonal activity, nutrient sensing, and bile acid metabolism are now being increasingly recognized.<xref ref-type="bibr" rid="article-150570.r26">[26]</xref><xref ref-type="bibr" rid="article-150570.r27">[27]</xref><xref ref-type="bibr" rid="article-150570.r28">[28]</xref>&#x000a0;</p>
        <p>RYGB has been shown to improve insulin sensitivity in many human trials. Furthermore,&#x000a0;increased levels of adiponectin (insulin-sensitizing hormone) and insulin receptors in muscles are observed. This promotes muscle fatty acid metabolism,&#x000a0;which decreases lipid accumulation in muscle and liver and improves insulin sensitization.<xref ref-type="bibr" rid="article-150570.r25">[25]</xref>&#x000a0;Another study demonstrated that RYGB&#x000a0;increases insulin secretion by both glucose-dependent and glucose-independent mechanisms.<xref ref-type="bibr" rid="article-150570.r26">[26]</xref>&#x000a0;Bariatric surgery is often referred to as metabolic surgery because of these effects.</p>
        <p>Extensive data exists that bariatric procedures&#x000a0;can control and even prevent&#x000a0;T2DM.<xref ref-type="bibr" rid="article-150570.r29">[29]</xref><xref ref-type="bibr" rid="article-150570.r30">[30]</xref><xref ref-type="bibr" rid="article-150570.r31">[31]</xref><xref ref-type="bibr" rid="article-150570.r32">[32]</xref><xref ref-type="bibr" rid="article-150570.r33">[33]</xref>&#x000a0;Most randomized controlled trials compared&#x000a0;surgical treatments and ILI for only&#x000a0;one to&#x000a0;2 years of follow-up, but a few collected data for five&#x000a0;years.<xref ref-type="bibr" rid="article-150570.r34">[34]</xref>&#x000a0;The mean hemoglobin A1c (HbA1c) reduction in the surgical group was about 2% compared to 0.5% in the conventional arm. Most of the surgical patients&#x000a0;reached an HbA1c of&#x000a0;nearly 6%. Remission of T2DM, defined as a non-diabetic HbA1c without medication, was also achieved in most patients. Sustained remission of T2DM has been documented in 30&#x000a0;to 60% of patients in multiple studies with follow-ups ranging from&#x000a0;1 to&#x000a0;5 years. The benefits of surgery may decrease with time, especially in&#x000a0;individuals&#x000a0;with poor control of T2DM in the preoperative period, longer duration of T2DM, and insulin use.<xref ref-type="bibr" rid="article-150570.r35">[35]</xref>&#x000a0;</p>
        <p>A relapse of T2DM was observed in 35&#x000a0;to 50% of the patients. In the same study, RYGB was associated with a median disease-free period of 8.3 years. Surgical treatment is associated with improved glycemic control and clinical outcome, even when remission does not occur. An observational study assessed diabetes remission and complications for 10 to 20 years and&#x000a0;noted a significant reduction in complications and higher remission rates in the surgical group.<xref ref-type="bibr" rid="article-150570.r36">[36]</xref>&#x000a0;</p>
        <p>RYGB and BPD patients experience the greatest reduction in HbA1c and BMI. Patients with a BMI&#x000a0;of 30-35 kg/m and uncontrolled T2DM have also been evaluated by many studies.<xref ref-type="bibr" rid="article-150570.r32">[32]</xref><xref ref-type="bibr" rid="article-150570.r37">[37]</xref><xref ref-type="bibr" rid="article-150570.r38">[38]</xref><xref ref-type="bibr" rid="article-150570.r31">[31]</xref>&#x000a0;The data consistently&#x000a0;show improved HbA1c and higher remission of T2DM in surgical patients. LAGB led to even better outcomes of T2DM in patients with a BMI&#x000a0;of 25&#x000a0;to 30 kg/m.<xref ref-type="bibr" rid="article-150570.r39">[39]</xref></p>
        <p>The economic impact of bariatric procedures has been studied in patients with T2DM. The cost per quality-adjusted life-year (QALY) for metabolic surgery is generally $3,200&#x000a0;to $6,300, below the $50,000 estimate for nonsurgical care.<xref ref-type="bibr" rid="article-150570.r2">[2]</xref>&#x000a0;A 15-year follow-up of the Swedish Obese Subjects (SOS) study&#x000a0;demonstrated no difference in total healthcare costs in patients with T2DM.<xref ref-type="bibr" rid="article-150570.r40">[40]</xref>&#x000a0;</p>
        <p>Metabolic surgery has become safer and more effective in the past two decades. Results are highly dependent&#x000a0;upon the operating surgeon. Mortality is low at 0.1&#x000a0;to 0.5%,&#x000a0;but discussing potential risks and complications&#x000a0;is&#x000a0;part of informed consent and&#x000a0;shared decision-making with patients.<xref ref-type="bibr" rid="article-150570.r2">[2]</xref><xref ref-type="bibr" rid="article-150570.r41">[41]</xref> Reoperation and readmission rates&#x000a0;are&#x000a0;2.5% and 5.1% for RYGB, 0.6% and 5.5% for VSG, and 0.6% and 2% for LAGB.<xref ref-type="bibr" rid="article-150570.r42">[42]</xref>&#x000a0;</p>
        <p>Long-term follow-up&#x000a0;demonstrates&#x000a0;that LAGB has the highest rate of removal or revision.&#x000a0;VSG is a newer&#x000a0;procedure that has increased in popularity as surgeons&#x000a0;gain additional experience. BPD is the most complex&#x000a0;surgery, resulting in&#x000a0;increased mortality, morbidity, and complications. Clinicians should educate all surgical patients about the risk of&#x000a0;postoperative nutritional deficiencies such as iron deficiency anemia, hypoglycemia, and bone demineralization&#x000a0;and&#x000a0;monitor them closely for short and long-term complications.</p>
      </sec>
      <sec id="article-150570.s4" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>Many quality metrics in healthcare evaluate the effectiveness of diabetes prevention and treatment. Obesity is a significant risk factor for T2DM and contributes to its severity. Early screening of patients with obesity and&#x000a0;intensive treatment can result in long-term improvement or remission of the disease. Strictly controlling&#x000a0;diabetes&#x000a0;decreases complications such as ketoacidosis, diabetic ulcers, amputations, soft tissue infections, and osteomyelitis. Furthermore, aggressively managing&#x000a0;HbA1c levels reduces the risk of coronary artery disease and chronic kidney disease.</p>
      </sec>
      <sec id="article-150570.s5" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Diabetes is a disabling chronic illness, and the obesity epidemic is increasing the incidence of this disease. Treatment of&#x000a0;obesity is the cornerstone in the prevention and management of T2DM. This requires&#x000a0;the combined efforts of every member of the healthcare team. An interdisciplinary approach will achieve the best clinical outcomes. The first step is the early recognition of patients with obesity in primary care practices. Nurses, the initial&#x000a0;medical contact, must accurately measure body weight and height and record the BMI. Nursing staff&#x000a0;should&#x000a0;review diet and physical activity at baseline and each follow-up visit. Patients&#x000a0;with elevated BMI are at higher risk for diabetes. All patients should&#x000a0;know their BMI category when discussing treatment options.&#x000a0;Clinicians&#x000a0;should help them set a personal weight loss goal, with a target of losing at least 10% of body weight, optimal for a positive&#x000a0;metabolic effect on diabetes. Intensive lifestyle interventions and pharmacotherapy&#x000a0;can be&#x000a0;prescribed following recommended guidelines.</p>
        <p>Suboptimal glycemic control should be addressed&#x000a0;at every visit. Inadequate weight loss (less than 10%) and persistent hyperglycemia should prompt a referral to medical obesity&#x000a0;specialists or bariatric surgeons. Physicians, surgeons, and other clinicians work&#x000a0;as a team in many weight loss programs. Obesity medicine&#x000a0;physicians&#x000a0;can help patients achieve the target weights necessary to become eligible for a surgical procedure. They also play a crucial role in the postoperative period, identifying complications and reinforcing&#x000a0;healthy behaviors for ongoing weight loss.&#x000a0;Many patients are ineligible for metabolic surgery due to potential operative risks from advanced cardiac or pulmonary disease. Obesity medicine&#x000a0;teams can still achieve&#x000a0;positive outcomes for this population.</p>
        <p>Registered dieticians, nutritionists, and therapists&#x000a0;are core members of&#x000a0;these teams&#x000a0;and&#x000a0;schedule frequent sessions to promote&#x000a0;optimal diet and exercise.&#x000a0;These teams can be led by trained dieticians, therapists, nurses, physicians, or surgeons. Endocrinology consultations provide additional treatment strategies for patients with persistent hyperglycemia. Preoperative assessment by a cardiologist&#x000a0;or a pulmonologist may be&#x000a0;required. High-risk patients should&#x000a0;undergo procedures in&#x000a0;centers with on-site cardiac and pulmonary critical care. Pharmacists&#x000a0;are invaluable in&#x000a0;managing medication dosages, especially in the perioperative setting.&#x000a0;Many&#x000a0;drugs are weight-based and require careful dose adjustments after surgery.</p>
        <p>The anesthesia&#x000a0;team evaluates patients&#x000a0;preoperatively and&#x000a0;treats anesthesia-related events during and after metabolic procedures. Physical therapists&#x000a0;help patients with&#x000a0;muscle strengthening in the postoperative period.&#x000a0;Because obesity is&#x000a0;often associated with mental health&#x000a0;conditions such as anxiety, depression, and body image disorders, psychiatry or psychology consultations should be considered if indicated.</p>
        <p>Obesity and T2DM are chronic, systemic conditions requiring&#x000a0;an interprofessional approach to prevention and management. Patients should be supported during their evaluation and treatment&#x000a0;and provided with ample resources by the multidisciplinary team to&#x000a0;make informed decisions about their care.</p>
      </sec>
      <sec id="article-150570.s6" sec-type="Nursing, Allied Health, and Interprofessional Team Interventions">
        <title>Nursing, Allied Health, and Interprofessional Team Interventions</title>
        <p>Interprofessional interventions target identifying&#x000a0;T2DM in patients with obesity. Providers should&#x000a0;be knowledgeable about&#x000a0;medications that promote weight gain and&#x000a0;consider alternatives. Nurses check the BMI&#x000a0;at each visit and alert the treating provider when the value exceeds&#x000a0;25 kg/m. These patients are screened for T2DM if that has not been done previously.&#x000a0;Primary care&#x000a0;clinicians recommend lifestyle interventions&#x000a0;for all patients with a BMI greater&#x000a0;than 25 kg/m. Standard written instructions about diet and exercise&#x000a0;are&#x000a0;reviewed at&#x000a0;each visit.</p>
        <p>Clinicians&#x000a0;help patients identify measurable weight loss goals&#x000a0;to reach a BMI less than 25 kg/m or a 5&#x000a0;to 10% weight loss.&#x000a0;A BMI greater than 30 kg/m alerts providers to consider ILI and&#x000a0;pharmacological treatments. Registered dieticians and nutritionists provide information for patients to&#x000a0;make&#x000a0;healthy dietary choices. A multidisciplinary approach with closed-loop&#x000a0;communication between primary care providers and endocrinologists can&#x000a0;improve outcomes. If ILI and pharmacotherapy fail to achieve adequate diabetes control and weight loss, timely referral to bariatric and metabolic surgeons is essential for optimal patient care.</p>
      </sec>
      <sec id="article-150570.s7" sec-type="Nursing, Allied Health, and Interprofessional Team Monitoring">
        <title>Nursing, Allied Health, and Interprofessional Team Monitoring</title>
        <p>Members of the interprofessional team&#x000a0;caring for&#x000a0;patients with diabetes and obesity monitor hbA1c, body weight, BMI, and lifestyle changes at each visit. When clinicians prescribe medications,&#x000a0;they&#x000a0;educate patients about side effects and&#x000a0;adjust doses when indicated. Pharmacists can reinforce and augment this counseling and perform medication reconciliation. After metabolic surgery, patients&#x000a0;are closely monitored by the interprofessional team.</p>
        <p>Frequently,&#x000a0;these patients require&#x000a0;fewer medications since metabolic parameters improve, and there is a higher risk of hypoglycemia.&#x000a0;Nurses should note any postoperative complications, including wound dehiscence, perforation, and signs of infection, and alert the treating providers. Clinicians, dieticians, and nutritionists monitor for signs of&#x000a0;metabolic derangements such as vitamin and mineral deficiencies or malabsorption syndromes. Avoiding continuous use of nonsteroidal anti-inflammatory medications in the first month&#x000a0;helps prevent erosion of anastomosis sites. Internal quality metrics&#x000a0;aid in assessing remission rates, the safety of procedures, the postoperative course, and long-term outcomes after surgery.</p>
        <p>Obesity is a risk factor for T2DM, cardiovascular disease, and other chronic health conditions. Effective healthcare teams actively screen for obesity and diabetes and use the BMI to classify the stages of obesity. ILI and&#x000a0;pharmacologic therapy&#x000a0;are utilized to achieve&#x000a0;a 10% weight loss. Patients with suboptimal weight loss and poor glycemic control despite maximal medical&#x000a0;treatment are referred for consideration of bariatric and metabolic surgery. Over the past two decades, bariatric surgery has become safer and more effective. Ongoing surveillance&#x000a0;following surgery identifies potential complications and monitors&#x000a0;results&#x000a0;to improve clinical outcomes.</p>
      </sec>
      <sec id="article-150570.s8">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=150570&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=150570">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/150570/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=150570">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-150570.s9">
        <fig id="article-150570.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Treatment options for type 2 diabetes mellitus and obesity Contributed by Kanica Yashi</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Type__2__diabetes__mellitus__and__Obesity" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-150570.s10">
        <title>References</title>
        <ref id="article-150570.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cohen</surname>
                <given-names>RV</given-names>
              </name>
              <name>
                <surname>Shikora</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Petry</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Caravatto</surname>
                <given-names>PP</given-names>
              </name>
              <name>
                <surname>Le Roux</surname>
                <given-names>CW</given-names>
              </name>
            </person-group>
            <article-title>The Diabetes Surgery Summit II Guidelines: a Disease-Based Clinical Recommendation.</article-title>
            <source>Obes Surg</source>
            <year>2016</year>
            <month>Aug</month>
            <volume>26</volume>
            <issue>8</issue>
            <fpage>1989</fpage>
            <page-range>1989-91</page-range>
            <pub-id pub-id-type="pmid">27189354</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150570.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rubino</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Nathan</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Eckel</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Schauer</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Alberti</surname>
                <given-names>KG</given-names>
              </name>
              <name>
                <surname>Zimmet</surname>
                <given-names>PZ</given-names>
              </name>
              <name>
                <surname>Del Prato</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ji</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Sadikot</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Herman</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Amiel</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Kaplan</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Taroncher-Oldenburg</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Cummings</surname>
                <given-names>DE</given-names>
              </name>
              <collab>Delegates of the 2nd Diabetes Surgery Summit</collab>
            </person-group>
            <article-title>Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations.</article-title>
            <source>Diabetes Care</source>
            <year>2016</year>
            <month>Jun</month>
            <volume>39</volume>
            <issue>6</issue>
            <fpage>861</fpage>
            <page-range>861-77</page-range>
            <pub-id pub-id-type="pmid">27222544</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150570.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Narayan</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Boyle</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Gregg</surname>
                <given-names>EW</given-names>
              </name>
              <name>
                <surname>Williamson</surname>
                <given-names>DF</given-names>
              </name>
            </person-group>
            <article-title>Effect of BMI on lifetime risk for diabetes in the U.S.</article-title>
            <source>Diabetes Care</source>
            <year>2007</year>
            <month>Jun</month>
            <volume>30</volume>
            <issue>6</issue>
            <fpage>1562</fpage>
            <page-range>1562-6</page-range>
            <pub-id pub-id-type="pmid">17372155</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150570.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Knowler</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Barrett-Connor</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Fowler</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Hamman</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Lachin</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Walker</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Nathan</surname>
                <given-names>DM</given-names>
              </name>
              <collab>Diabetes Prevention Program Research Group</collab>
            </person-group>
            <article-title>Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.</article-title>
            <source>N Engl J Med</source>
            <year>2002</year>
            <month>Feb</month>
            <day>07</day>
            <volume>346</volume>
            <issue>6</issue>
            <fpage>393</fpage>
            <page-range>393-403</page-range>
            <pub-id pub-id-type="pmid">11832527</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150570.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Booth</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Prevost</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Reddy</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dregan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Charlton</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ashworth</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rudisill</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Littlejohns</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gulliford</surname>
                <given-names>MC</given-names>
              </name>
            </person-group>
            <article-title>Incidence of type 2 diabetes after bariatric surgery: population-based matched cohort study.</article-title>
            <source>Lancet Diabetes Endocrinol</source>
            <year>2014</year>
            <month>Dec</month>
            <volume>2</volume>
            <issue>12</issue>
            <fpage>963</fpage>
            <page-range>963-8</page-range>
            <pub-id pub-id-type="pmid">25466723</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150570.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kahan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fujioka</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Obesity Pharmacotherapy in Patients With Type 2 Diabetes.</article-title>
            <source>Diabetes Spectr</source>
            <year>2017</year>
            <month>Nov</month>
            <volume>30</volume>
            <issue>4</issue>
            <fpage>250</fpage>
            <page-range>250-257</page-range>
            <pub-id pub-id-type="pmid">29151715</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150570.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Misra</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Ethnic-Specific Criteria for Classification of Body Mass Index: A Perspective for Asian Indians and American Diabetes Association Position Statement.</article-title>
            <source>Diabetes Technol Ther</source>
            <year>2015</year>
            <month>Sep</month>
            <volume>17</volume>
            <issue>9</issue>
            <fpage>667</fpage>
            <page-range>667-71</page-range>
            <pub-id pub-id-type="pmid">25902357</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150570.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Powers</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Bardsley</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Cypress</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Funnell</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Harms</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hess-Fischl</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hooks</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Isaacs</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Mandel</surname>
                <given-names>ED</given-names>
              </name>
              <name>
                <surname>Maryniuk</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Norton</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rinker</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Siminerio</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Uelmen</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Diabetes Self-management Education and Support in Adults With Type 2 Diabetes: A Consensus Report of the American Diabetes Association, the Association of Diabetes Care &#x00026; Education Specialists, the Academy of Nutrition and Dietetics, the American Academy of Family Physicians, the American Academy of PAs, the American Association of Nurse Practitioners, and the American Pharmacists Association.</article-title>
            <source>Diabetes Care</source>
            <year>2020</year>
            <month>Jul</month>
            <volume>43</volume>
            <issue>7</issue>
            <fpage>1636</fpage>
            <page-range>1636-1649</page-range>
            <pub-id pub-id-type="pmid">32513817</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150570.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <collab>American Diabetes Association</collab>
            <article-title>5. Facilitating Behavior Change and Well-being to Improve Health Outcomes: <italic>Standards of Medical Care in Diabetes-2021</italic>.</article-title>
            <source>Diabetes Care</source>
            <year>2021</year>
            <month>Jan</month>
            <volume>44</volume>
            <issue>Suppl 1</issue>
            <fpage>S53</fpage>
            <page-range>S53-S72</page-range>
            <pub-id pub-id-type="pmid">33298416</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150570.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Franz</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Boucher</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Rutten-Ramos</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>VanWormer</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>Lifestyle weight-loss intervention outcomes in overweight and obese adults with type 2 diabetes: a systematic review and meta-analysis of randomized clinical trials.</article-title>
            <source>J Acad Nutr Diet</source>
            <year>2015</year>
            <month>Sep</month>
            <volume>115</volume>
            <issue>9</issue>
            <fpage>1447</fpage>
            <page-range>1447-63</page-range>
            <pub-id pub-id-type="pmid">25935570</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150570.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <collab>Look AHEAD Research Group</collab>
            <article-title>Eight-year weight losses with an intensive lifestyle intervention: the look AHEAD study.</article-title>
            <source>Obesity (Silver Spring)</source>
            <year>2014</year>
            <month>Jan</month>
            <volume>22</volume>
            <issue>1</issue>
            <fpage>5</fpage>
            <page-range>5-13</page-range>
            <pub-id pub-id-type="pmid">24307184</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150570.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Azadbakht</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Fard</surname>
                <given-names>NR</given-names>
              </name>
              <name>
                <surname>Karimi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Baghaei</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Surkan</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Rahimi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Esmaillzadeh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Willett</surname>
                <given-names>WC</given-names>
              </name>
            </person-group>
            <article-title>Effects of the Dietary Approaches to Stop Hypertension (DASH) eating plan on cardiovascular risks among type 2 diabetic patients: a randomized crossover clinical trial.</article-title>
            <source>Diabetes Care</source>
            <year>2011</year>
            <month>Jan</month>
            <volume>34</volume>
            <issue>1</issue>
            <fpage>55</fpage>
            <page-range>55-7</page-range>
            <pub-id pub-id-type="pmid">20843978</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150570.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>D'Innocenzo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Biagi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lanari</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Obesity and the Mediterranean Diet: A Review of Evidence of the Role and Sustainability of the Mediterranean Diet.</article-title>
            <source>Nutrients</source>
            <year>2019</year>
            <month>Jun</month>
            <day>09</day>
            <volume>11</volume>
            <issue>6</issue>
            <pub-id pub-id-type="pmid">31181836</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150570.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Patikorn</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Roubal</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Veettil</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Chandran</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Pham</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>YY</given-names>
              </name>
              <name>
                <surname>Giovannucci</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Varady</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Chaiyakunapruk</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Intermittent Fasting and Obesity-Related Health Outcomes: An Umbrella Review of Meta-analyses of Randomized Clinical Trials.</article-title>
            <source>JAMA Netw Open</source>
            <year>2021</year>
            <month>Dec</month>
            <day>01</day>
            <volume>4</volume>
            <issue>12</issue>
            <fpage>e2139558</fpage>
            <pub-id pub-id-type="pmid">34919135</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150570.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Little</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Gillen</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Percival</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Safdar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tarnopolsky</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Punthakee</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Jung</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Gibala</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Low-volume high-intensity interval training reduces hyperglycemia and increases muscle mitochondrial capacity in patients with type 2 diabetes.</article-title>
            <source>J Appl Physiol (1985)</source>
            <year>2011</year>
            <month>Dec</month>
            <volume>111</volume>
            <issue>6</issue>
            <fpage>1554</fpage>
            <page-range>1554-60</page-range>
            <pub-id pub-id-type="pmid">21868679</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150570.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kulzer</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Albus</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Herpertz</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kruse</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lange</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lederbogen</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Petrak</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Psychosocial Factors and Diabetes.</article-title>
            <source>Exp Clin Endocrinol Diabetes</source>
            <year>2023</year>
            <month>Feb</month>
            <volume>131</volume>
            <issue>1-02</issue>
            <fpage>94</fpage>
            <page-range>94-109</page-range>
            <pub-id pub-id-type="pmid">36731492</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150570.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Annesi</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>Moderation of Mood in the Transfer of Self-Regulation From an Exercise to an Eating Context: Short- and Long-Term Effects on Dietary Change and Obesity in Women.</article-title>
            <source>Int J Behav Med</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>26</volume>
            <issue>3</issue>
            <fpage>323</fpage>
            <page-range>323-328</page-range>
            <pub-id pub-id-type="pmid">30734155</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150570.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maddatu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Anderson-Baucum</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Evans-Molina</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Smoking and the risk of type 2 diabetes.</article-title>
            <source>Transl Res</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>184</volume>
            <fpage>101</fpage>
            <page-range>101-107</page-range>
            <pub-id pub-id-type="pmid">28336465</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150570.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Son</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Comprehensive Review of Current and Upcoming Anti-Obesity Drugs.</article-title>
            <source>Diabetes Metab J</source>
            <year>2020</year>
            <month>Dec</month>
            <volume>44</volume>
            <issue>6</issue>
            <fpage>802</fpage>
            <page-range>802-818</page-range>
            <pub-id pub-id-type="pmid">33389955</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150570.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Garvey</surname>
                <given-names>WT</given-names>
              </name>
              <name>
                <surname>Ryan</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Look</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gadde</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Allison</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Peterson</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Schwiers</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Day</surname>
                <given-names>WW</given-names>
              </name>
              <name>
                <surname>Bowden</surname>
                <given-names>CH</given-names>
              </name>
            </person-group>
            <article-title>Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study.</article-title>
            <source>Am J Clin Nutr</source>
            <year>2012</year>
            <month>Feb</month>
            <volume>95</volume>
            <issue>2</issue>
            <fpage>297</fpage>
            <page-range>297-308</page-range>
            <pub-id pub-id-type="pmid">22158731</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150570.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Davies</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Bergenstal</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bode</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kushner</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Lewin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Skj&#x000f8;th</surname>
                <given-names>TV</given-names>
              </name>
              <name>
                <surname>Andreasen</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Jensen</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>DeFronzo</surname>
                <given-names>RA</given-names>
              </name>
              <collab>NN8022-1922 Study Group</collab>
            </person-group>
            <article-title>Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.</article-title>
            <source>JAMA</source>
            <year>2015</year>
            <month>Aug</month>
            <day>18</day>
            <volume>314</volume>
            <issue>7</issue>
            <fpage>687</fpage>
            <page-range>687-99</page-range>
            <pub-id pub-id-type="pmid">26284720</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150570.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wilding</surname>
                <given-names>JPH</given-names>
              </name>
              <name>
                <surname>Batterham</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Calanna</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Davies</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Van Gaal</surname>
                <given-names>LF</given-names>
              </name>
              <name>
                <surname>Lingvay</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>McGowan</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Rosenstock</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tran</surname>
                <given-names>MTD</given-names>
              </name>
              <name>
                <surname>Wadden</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Wharton</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yokote</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Zeuthen</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kushner</surname>
                <given-names>RF</given-names>
              </name>
              <collab>STEP 1 Study Group</collab>
            </person-group>
            <article-title>Once-Weekly Semaglutide in Adults with Overweight or Obesity.</article-title>
            <source>N Engl J Med</source>
            <year>2021</year>
            <month>Mar</month>
            <day>18</day>
            <volume>384</volume>
            <issue>11</issue>
            <fpage>989</fpage>
            <page-range>989-1002</page-range>
            <pub-id pub-id-type="pmid">33567185</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150570.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jastreboff</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Aronne</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Ahmad</surname>
                <given-names>NN</given-names>
              </name>
              <name>
                <surname>Wharton</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Connery</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Alves</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kiyosue</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bunck</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Stefanski</surname>
                <given-names>A</given-names>
              </name>
              <collab>SURMOUNT-1 Investigators</collab>
            </person-group>
            <article-title>Tirzepatide Once Weekly for the Treatment of Obesity.</article-title>
            <source>N Engl J Med</source>
            <year>2022</year>
            <month>Jul</month>
            <day>21</day>
            <volume>387</volume>
            <issue>3</issue>
            <fpage>205</fpage>
            <page-range>205-216</page-range>
            <pub-id pub-id-type="pmid">35658024</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150570.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Torgerson</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Hauptman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Boldrin</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>Sj&#x000f6;str&#x000f6;m</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients.</article-title>
            <source>Diabetes Care</source>
            <year>2004</year>
            <month>Jan</month>
            <volume>27</volume>
            <issue>1</issue>
            <fpage>155</fpage>
            <page-range>155-61</page-range>
            <pub-id pub-id-type="pmid">14693982</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150570.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thaler</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Cummings</surname>
                <given-names>DE</given-names>
              </name>
            </person-group>
            <article-title>Minireview: Hormonal and metabolic mechanisms of diabetes remission after gastrointestinal surgery.</article-title>
            <source>Endocrinology</source>
            <year>2009</year>
            <month>Jun</month>
            <volume>150</volume>
            <issue>6</issue>
            <fpage>2518</fpage>
            <page-range>2518-25</page-range>
            <pub-id pub-id-type="pmid">19372197</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150570.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Salehi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Woods</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>D'Alessio</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>Gastric bypass alters both glucose-dependent and glucose-independent regulation of islet hormone secretion.</article-title>
            <source>Obesity (Silver Spring)</source>
            <year>2015</year>
            <month>Oct</month>
            <volume>23</volume>
            <issue>10</issue>
            <fpage>2046</fpage>
            <page-range>2046-52</page-range>
            <pub-id pub-id-type="pmid">26316298</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150570.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tremaroli</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Karlsson</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Werling</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>St&#x000e5;hlman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kovatcheva-Datchary</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Olbers</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>F&#x000e4;ndriks</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>le Roux</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Nielsen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>B&#x000e4;ckhed</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Roux-en-Y Gastric Bypass and Vertical Banded Gastroplasty Induce Long-Term Changes on the Human Gut Microbiome Contributing to Fat Mass Regulation.</article-title>
            <source>Cell Metab</source>
            <year>2015</year>
            <month>Aug</month>
            <day>04</day>
            <volume>22</volume>
            <issue>2</issue>
            <fpage>228</fpage>
            <page-range>228-38</page-range>
            <pub-id pub-id-type="pmid">26244932</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150570.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Breen</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Rasmussen</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Kokorovic</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cheung</surname>
                <given-names>GW</given-names>
              </name>
              <name>
                <surname>Lam</surname>
                <given-names>TK</given-names>
              </name>
            </person-group>
            <article-title>Jejunal nutrient sensing is required for duodenal-jejunal bypass surgery to rapidly lower glucose concentrations in uncontrolled diabetes.</article-title>
            <source>Nat Med</source>
            <year>2012</year>
            <month>Jun</month>
            <volume>18</volume>
            <issue>6</issue>
            <fpage>950</fpage>
            <page-range>950-5</page-range>
            <pub-id pub-id-type="pmid">22610279</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150570.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mingrone</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Panunzi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>De Gaetano</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Guidone</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Iaconelli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Leccesi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Nanni</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Pomp</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Castagneto</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ghirlanda</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Rubino</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Bariatric surgery versus conventional medical therapy for type 2 diabetes.</article-title>
            <source>N Engl J Med</source>
            <year>2012</year>
            <month>Apr</month>
            <day>26</day>
            <volume>366</volume>
            <issue>17</issue>
            <fpage>1577</fpage>
            <page-range>1577-85</page-range>
            <pub-id pub-id-type="pmid">22449317</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150570.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schauer</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Kashyap</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Wolski</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Brethauer</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Kirwan</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Pothier</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Abood</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Nissen</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Bhatt</surname>
                <given-names>DL</given-names>
              </name>
            </person-group>
            <article-title>Bariatric surgery versus intensive medical therapy in obese patients with diabetes.</article-title>
            <source>N Engl J Med</source>
            <year>2012</year>
            <month>Apr</month>
            <day>26</day>
            <volume>366</volume>
            <issue>17</issue>
            <fpage>1567</fpage>
            <page-range>1567-76</page-range>
            <pub-id pub-id-type="pmid">22449319</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150570.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ikramuddin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Korner</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Connett</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Inabnet</surname>
                <given-names>WB</given-names>
              </name>
              <name>
                <surname>Billington</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Leslie</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Chong</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Jeffery</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Ahmed</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Vella</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chuang</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Bessler</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sarr</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Swain</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Laqua</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Jensen</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Bantle</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia: the Diabetes Surgery Study randomized clinical trial.</article-title>
            <source>JAMA</source>
            <year>2013</year>
            <month>Jun</month>
            <day>05</day>
            <volume>309</volume>
            <issue>21</issue>
            <fpage>2240</fpage>
            <page-range>2240-9</page-range>
            <pub-id pub-id-type="pmid">23736733</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150570.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Parikh</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sheth</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>McMacken</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zahra</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Saunders</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Ude-Welcome</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dunn</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ogedegbe</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Schmidt</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Pachter</surname>
                <given-names>HL</given-names>
              </name>
            </person-group>
            <article-title>Randomized pilot trial of bariatric surgery versus intensive medical weight management on diabetes remission in type 2 diabetic patients who do NOT meet NIH criteria for surgery and the role of soluble RAGE as a novel biomarker of success.</article-title>
            <source>Ann Surg</source>
            <year>2014</year>
            <month>Oct</month>
            <volume>260</volume>
            <issue>4</issue>
            <fpage>617</fpage>
            <page-range>617-22; discussion 622-4</page-range>
            <pub-id pub-id-type="pmid">25203878</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150570.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ding</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Simonson</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Wewalka</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Halperin</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Foster</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Goebel-Fabbri</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hamdy</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Clancy</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lautz</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Vernon</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Goldfine</surname>
                <given-names>AB</given-names>
              </name>
            </person-group>
            <article-title>Adjustable Gastric Band Surgery or Medical Management in Patients With Type 2 Diabetes: A Randomized Clinical Trial.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2015</year>
            <month>Jul</month>
            <volume>100</volume>
            <issue>7</issue>
            <fpage>2546</fpage>
            <page-range>2546-56</page-range>
            <pub-id pub-id-type="pmid">25909333</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150570.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mingrone</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Panunzi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>De Gaetano</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Guidone</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Iaconelli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nanni</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Castagneto</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bornstein</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rubino</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Bariatric-metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre, randomised controlled trial.</article-title>
            <source>Lancet</source>
            <year>2015</year>
            <month>Sep</month>
            <day>05</day>
            <volume>386</volume>
            <issue>9997</issue>
            <fpage>964</fpage>
            <page-range>964-73</page-range>
            <pub-id pub-id-type="pmid">26369473</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150570.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arterburn</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Bogart</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sherwood</surname>
                <given-names>NE</given-names>
              </name>
              <name>
                <surname>Sidney</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Coleman</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Haneuse</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>O'Connor</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Theis</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Campos</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>McCulloch</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Selby</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>A multisite study of long-term remission and relapse of type 2 diabetes mellitus following gastric bypass.</article-title>
            <source>Obes Surg</source>
            <year>2013</year>
            <month>Jan</month>
            <volume>23</volume>
            <issue>1</issue>
            <fpage>93</fpage>
            <page-range>93-102</page-range>
            <pub-id pub-id-type="pmid">23161525</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150570.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sj&#x000f6;str&#x000f6;m</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Peltonen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jacobson</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ahlin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Andersson-Assarsson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Anveden</surname>
                <given-names>&#x000c5;</given-names>
              </name>
              <name>
                <surname>Bouchard</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Carlsson</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Karason</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>L&#x000f6;nroth</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>N&#x000e4;slund</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Sj&#x000f6;str&#x000f6;m</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Taube</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wedel</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Svensson</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Sj&#x000f6;holm</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Carlsson</surname>
                <given-names>LM</given-names>
              </name>
            </person-group>
            <article-title>Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications.</article-title>
            <source>JAMA</source>
            <year>2014</year>
            <month>Jun</month>
            <day>11</day>
            <volume>311</volume>
            <issue>22</issue>
            <fpage>2297</fpage>
            <page-range>2297-304</page-range>
            <pub-id pub-id-type="pmid">24915261</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150570.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ouyang</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>Effect of laparoscopic Roux-en-Y gastric bypass surgery on type 2 diabetes mellitus with hypertension: a randomized controlled trial.</article-title>
            <source>Diabetes Res Clin Pract</source>
            <year>2013</year>
            <month>Jul</month>
            <volume>101</volume>
            <issue>1</issue>
            <fpage>50</fpage>
            <page-range>50-6</page-range>
            <pub-id pub-id-type="pmid">23706413</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150570.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Courcoulas</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Goodpaster</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Eagleton</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Belle</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Kalarchian</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Lang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Toledo</surname>
                <given-names>FG</given-names>
              </name>
              <name>
                <surname>Jakicic</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Surgical vs medical treatments for type 2 diabetes mellitus: a randomized clinical trial.</article-title>
            <source>JAMA Surg</source>
            <year>2014</year>
            <month>Jul</month>
            <volume>149</volume>
            <issue>7</issue>
            <fpage>707</fpage>
            <page-range>707-15</page-range>
            <pub-id pub-id-type="pmid">24899268</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150570.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wentworth</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Playfair</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Laurie</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ritchie</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Burton</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Shaw</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>O'Brien</surname>
                <given-names>PE</given-names>
              </name>
            </person-group>
            <article-title>Multidisciplinary diabetes care with and without bariatric surgery in overweight people: a randomised controlled trial.</article-title>
            <source>Lancet Diabetes Endocrinol</source>
            <year>2014</year>
            <month>Jul</month>
            <volume>2</volume>
            <issue>7</issue>
            <fpage>545</fpage>
            <page-range>545-52</page-range>
            <pub-id pub-id-type="pmid">24731535</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150570.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Keating</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Neovius</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sj&#x000f6;holm</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Peltonen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Narbro</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Eriksson</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Sj&#x000f6;str&#x000f6;m</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Carlsson</surname>
                <given-names>LM</given-names>
              </name>
            </person-group>
            <article-title>Health-care costs over 15 years after bariatric surgery for patients with different baseline glucose status: results from the Swedish Obese Subjects study.</article-title>
            <source>Lancet Diabetes Endocrinol</source>
            <year>2015</year>
            <month>Nov</month>
            <volume>3</volume>
            <issue>11</issue>
            <fpage>855</fpage>
            <page-range>855-65</page-range>
            <pub-id pub-id-type="pmid">26386667</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150570.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aminian</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Brethauer</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Kirwan</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Kashyap</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Burguera</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Schauer</surname>
                <given-names>PR</given-names>
              </name>
            </person-group>
            <article-title>How safe is metabolic/diabetes surgery?</article-title>
            <source>Diabetes Obes Metab</source>
            <year>2015</year>
            <month>Feb</month>
            <volume>17</volume>
            <issue>2</issue>
            <fpage>198</fpage>
            <page-range>198-201</page-range>
            <pub-id pub-id-type="pmid">25352176</pub-id>
          </element-citation>
        </ref>
        <ref id="article-150570.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Birkmeyer</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Dimick</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Share</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hawasli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>English</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Genaw</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Finks</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Carlin</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Birkmeyer</surname>
                <given-names>JD</given-names>
              </name>
              <collab>Michigan Bariatric Surgery Collaborative</collab>
            </person-group>
            <article-title>Hospital complication rates with bariatric surgery in Michigan.</article-title>
            <source>JAMA</source>
            <year>2010</year>
            <month>Jul</month>
            <day>28</day>
            <volume>304</volume>
            <issue>4</issue>
            <fpage>435</fpage>
            <page-range>435-42</page-range>
            <pub-id pub-id-type="pmid">20664044</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
